HVTN 703 / HPTN 081 (The AMP Study)

Principal Investigator(s):Lawrence Corey, Myron Cohen
Objective:This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection in high-risk, HIV-uninfected women.The study also looks at the safety of these antibody infusions and it looks over time at how much antibody is in the blood of study participants receiving different amounts or doses of the antibody.Read more in Understanding Results of the AMP Trials Last updated August 9, 2022
Start Date
End Date
May 1, 2016
March 3, 2021
Age range: 18 Years ↔ 50 Years
Population:Cisgender Women